Below is a bibliography of Travere’s peer-reviewed manuscripts in reverse chronological order.



Howard Trachtman, Ulysses Diva, Edward Murphy, Kaijun Wang, Jula Inrig, Radko Komers. Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial. Kidney International Reports 2023 In Press

Dawn J. Caster, Clint W. Abner, Patrick D. Walker, Kaijun Wang, Jihaeng Heo, Andrew R. Rava, and Martin Bunke. Clinicopathological Characteristics of Adult IgA Nephropathy in the United States. KI Reports 2023 In Press

Edgar V. Lerma, Mark E. Bensink, Kamlesh M. Thakker, Richard Lieblich, Martin Bunke, Andrew Rava, Kaijun Wang, Michael V. Murphy, David Oliveri, Diana T. Amari, David M. W. Cork, and Juan Carlos Q. Velez. Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis. Kidney Medicine 2023 In Press

Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V, and PROTECT investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised double-blind active-controlled clinical trial. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.

Chen SC, Cai D, Winnett C, Nguyen M. Verma N, Liu K, Preciado, P. Effect of multiple doses of sparsentan on the single-dose pharmacokinetics of dapagliflozin: An open-label drug-drug interaction study in healthy adults. Clin Pharmacol Drug Dev. 2023 May;12(5):535-541. doi: 10.1002/cpdd.1231. Epub 2023 Feb 28.

Jhaveri KD, Bensink ME, Bunke M, Briggs JA, Cork DMW, Jeyabalan A. Humanistic and economic burden of IgA-nephropathy: systematic literature reviews and narrative synthesis. Pharmacoecon Open. 2023 Apr 27. doi: 10.1007/s41669-023-00415-0.

Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023 Apr 13. doi: 10.2215/CJN.0000000000000135.

Barratt J, Rovin B, Wong MG, Trimarchi H, Perkovic V, and on behalf of the PROTECT investigators. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May.

Pramparo T, Steiner RD, Rodems S, Jenkinson C. Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis, Orphanet J Rare Dis. 2023 Jan 17;18(1):13. doi: 10.1186/s13023-022-02578-1.



Mikel C, Goldfarb DS, Ponte A, Steigelman K, Latyshev S, Goldfarb D. Accurate 24-h urine cystine quantification for patients on cystine-binding thiol drugs. Urolithiasis. 2022 Dec;50(6):721-727. doi: 10.1007/s00240-022-01364-9. Epub 2022 Oct 6.

Caster D, Magalhaes B, Pennese N, Zaffalon A, Faiella M, Campbell K, Radhakrishnan J, Tesař V, Trachtman H. Efficacy and safety of immunosuppressive therapy in primary FSGS: a systematic review and meta-analysis.  Kidney Med. 2022 Jun 11;4(8):100501. doi:10.1016/j.xkme.2022.100501.

Floege J, Barratt J, Coppo R, Lafayette R, Radhakrishnan J, Reich H, Rovin B, Selewski D, Vivarelli M, Pham C, Tesař V. International Physicians Delphi survey: managing patients with Immunoglobulin A nephropathy. Kidney Int Rep. 2022 May 26;7(9):2076-2080. doi: 10.1016/j.ekir.2022.05.022.

Campbell K, Pennese N, Zaffalon A, Magalhaes B, Faiella M, Caster D, Radhakrishnan J, Tesař V, Trachtman H. Efficacy and safety of ACE inhibitor and ARB therapies in primary FSGS treatment: a systematic review and meta-analysis. Kidney Med. 2022 Mar 24;4(5):100457. doi: 10.1016/j.xkme.2022.100457.



Sanchez P, Farkhondeh A, Pavlinov I, Baumgaertel K, Rodems S, Zheng W. Therapeutics development for Alagille syndrome. Front Pharmacol. 2021 Aug 23;12:704586. doi: 10.3389/fphar.2021.704586. eCollection 2021.

Brooks BM, Pradhan M, Cheng YS, Gorshkov K, Farkhondeh A, Chen CZ, Beers J, Liu C, Baumgaertel K, Rodems S, Zheng W. Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936 T > A) mutation in JAGGED-1. Stem Cell Res. 2021 Jul;54:102447. doi: 10.1016/j.scr.2021.102447. Epub 2021 Jun 24.

Zhu W, Cheng YS, Xu M, Farkhondeh A, Beers J, Zou J, Liu C, Baumgaertel K, Rodems S, Zheng W. Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. Stem Cell Res. 2021 May;53:102366. doi: 10.1016/j.scr.2021.102366. Epub 2021 Apr 27.



Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study design of the Phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. Apr 2020;5(4):494-502. doi:10.1016/j.ekir.2019.12.017.

Trachtman H, Hogan J, Tesař V, Komers R. Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy. Drugs of the Future. 2020;45(2):79-98. doi:10.1358/dof.2020.45.2.3058863.



Barratt J, Rovin B, Diva U, Mercer A, Komers R, Group PSD. Implementing the Kidney Health Initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT Trial). Kidney Int Rep. Nov 2019;4(11):1633-1637. doi:10.1016/j.ekir.2019.08.007.

Modersitzki F, Goldfarb DS, Goldstein RL, Sur RL, Penniston KL. Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. Urolithiasis. 2020 Aug;48(4):313-320. doi: 10.1007/s00240-019-01174-6. Epub 2019 Dec 13.



Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesař V, Zhdanova O, Komers R; DUET Study Group. DUET: A Phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. Nov 2018;29(11):2745-2754. doi:10.1681/ASN.2018010091.



Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep. Jul 2017;2(4):654-664. doi:10.1016/j.ekir.2017.02.019.



Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. May 15 2016;310(10):R877-84. doi:10.1152/ajpregu.00425.2015.



RET246  07/2023